An investigation on behalf of investors, who currently hold shares of Juno Therapeutics Inc (NASDAQ:JUNO), was announced concerning whether the takeover of Juno Therapeutics Inc. by Celgene Corporation for $87 per share is unfair to NASDAQ:JUNO stockholders.

The investigation by a law firm concerns whether certain officers and directors of Juno Therapeutics Inc breached their fiduciary duties owed to NASDAQ:JUNO investors in connection with the proposed acquisition.

Seattle, WA based Juno Therapeutics Inc is a biopharmaceutical company, which is focused on developing cellular immunotherapies for the treatment of cancer. Juno Therapeutics Inc reported that its annual Total Revenue rose from $18.21 million in 2015 to $79.36 million in 2016. On Janaury 22, 2018, Celgene Corporation (NASDAQ:CELG) and Juno Therapeutics, Inc.(NASDAQ:JUNO) announced the signing of a merger agreement in which Celgene has agreed to acquire Juno Therapeutics Inc. Under the terms of the merger agreement, Celgene will pay $87 per share in cash, or a total of approximately $9 billion, net of cash.

However, the investigation concerns whether the offer is unfair to Juno Therapeutics Inc (NASDAQ:JUNO stockholders. More specifically, the investigation concerns whether the Juno Therapeutics Inc (NASDAQ:JUNO Board of Directors undertook an adequate sales process, adequately shopped the company before entering into the transaction, maximized shareholder value by negotiating the best price, and acted in the shareholders' best interests in connection with the proposed sale.

On January 31, 2018, NASDAQ:JUNO shares closed at $85.81 per share.